Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Impact · against what's priced in

Rhelion Life Sciences progresses toward its 2027 clinical trial goals with the successful extraction of IBEX011. The commencement of stability testing represents a necessary technical step in the drug development pipeline.

RHEL+0.40: No priced-in read yet

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

What matters in this story

Tiziana's experimental MS treatment meets main goals in mid-stage study

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

What matters in this story

Tiziana's experimental MS treatment meets main goals in mid-stage study

How each ticker is affected

Track these names every morning.

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

Should You Invest $1,000 in BridgeBio Pharma Right Now?

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

What matters in this story

Next reads from the same story arc

Tiziana's experimental MS treatment meets main goals in mid-stage study

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

What matters in this story

Next reads from the same story arc

Tiziana's experimental MS treatment meets main goals in mid-stage study

How each ticker is affected

Track these names every morning.

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

Should You Invest $1,000 in BridgeBio Pharma Right Now?

Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade

BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?